Tracers / [177Lu]Lu-PEG-(DOTA)1
[177Lu]Lu-PEG-(DOTA)1
Also written as [Lu-177]PEG-(DOTA)1
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PEGylated DOTA-chelated nanocarrier (non-targeted control, lacking PSMA-binding ligand)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 70.9-76.6% | — | PEG-(DOTA)1 | 38700450 2024 Adv Healthc Mater StarPEG nanocarrier in water was added to a solution of 10 mM NH4OAc containing 10 vol% of ascorbic acid (20 mg/mL) and 177LuCl4 in a ratio of 0.37 MBq/μg of nanocarriers were mixed to it. — the isolated yield and molar activities for [177Lu]PEG-(DOTA)1 ranged from 70.9-76.6% and 10.8-11.5 MBq/nmol, respectively |
Need this precursor?We can point you to suppliers for [177Lu]Lu-PEG-(DOTA)1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38700450. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38700450: 'PEG-(DOTA)1 (Yield 93%, 90 mg)'.